Bridge-Funded Research

The Bridge Project focuses on bringing into the lives of patients new technical advances related to cancer detection and monitoring, targeted drug delivery, rapid mapping of drug resistance, and sustaining cancer-specific immune responses.

Bridge Project funding is currently being applied to make advances in the treatment of several cancer types that represent areas of great clinical need:

  • Brain cancer
  • Pancreatic cancer
  • Lung cancer
  • Melanoma
  • Ovarian cancer
  • Advanced prostate cancer
  • Advanced breast cancer
  • Leukemia (adult)
  • Myelodysplastic syndromes

The Bridge Project also welcomes proposals in the following areas:

  • Cachexia in cancer
  • Cancers with viral etiology (e.g., Merkel cell carcinoma)
  • New technologies for tumor monitoring

Bridge-Project Awardees include:

  • Single-Cell Functional, Genomic and Transcriptomic Analysis in Glioblastoma," a collaboration between Keith L. Ligon of Dana-Farber Cancer Institute, J. Christopher Love of the Koch Institute, and Matthew Meyerson of Dana-Farber Cancer Institute and the Broad Institute.
  • "Angiotensin Receptor Blockers (ARBs) as a Novel Approach to Improve Drug Delivery in the Treatment of Pancreatic Cancer," a collaboration between Rakesh K. Jain of Massachusetts General Hospital and Robert S. Langer of the Koch Institute
  • "A Pancreatobiliary Chemotherapy Eluting Stent for Pancreatic Ductal Adenocarcinomas," a collaboration between Jeffrey W. Clark of Massachusetts General Hospital, Robert S. Langer of the Koch Institute, and Elazer Edelman of the Institute of Medical Engineering and Sciences at MIT and the Koch Institute
  • Novel Immunotherapies Against Pancreatic Cancer," a collaboration between Hidde Ploegh of the Whitehead and Koch Institutes, Kai W. Wucherpfennig of Dana-Farber Cancer Institute, and J. Christopher Love of the Koch Institute
  • "Targeting Mutant IDH1 in Malignant Gliomas," a collaboration between Matthew Vander Heiden of the Koch Institute, William G. Kaelin, Jr. of Dana-Farber Cancer Institute, and Daniel Cahill of Massachusetts General Hospital
  • "Developing Novel Therapeutic Approaches in Small Cell Lung Carcinoma Using Genetically Engineered Mouse Models and Human Circulating Tumor Cells," a collaboration between Tyler Jacks of the Koch Institute, Jeffrey Engelman of Massachusetts General Hospital, and Daniel Haber of Massachusetts General Hospital
  • "Osmotic Micro-Pump as Delivery System for Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer," a collaboration between Michael Cima of the Koch Institute, Michael Birrer of Massachusetts General Hospital, and Marcela Del Carmen of Massachusetts General Hospital
  • "Detection of 'Invisible' Nevi in Redheads," a collaboration between Peter So of the MIT Departments of Mechanical Engineering and Biological Engineering, Conor Evans of Massachusetts General Hospital, and David Fisher of Massachusetts General Hospital
  •  "Novel Agents for Targeting MCL-1 in  Adult AML/ALL," a collaboration between Amy Keating of MIT Department of Biology, Loren Walensky of Dana-Farber Cancer Institute, and Anthony Letai of Dana-Farber Cancer Institute
  • "Development of a Prototype Instrument Based on a Second-window Near-infrared Fluorescence Optical Imaging Modality for Detection and Monitoring of Deep-tissue Ovarian and Pancreatic Cancers," a collaboration between Angela Belcher of the Koch Institute, Michael Birrer of Massachusetts General Hospital, and Marcela del Carmen of Massachusetts General Hospital
  •  "Development of an ALK Vaccine for Lung Cancer Treatment," a collaboration between Roberto Chiarle of Boston Children's Hospital and Darrell Irvine of the Koch Institute
  • "Targeting Transcriptional Amplification for the Treatment of SCLC Using a CDK7 Inhibitor," Nathanael Gray of Dana-Farber Cancer Institute, Kwok-Kin Wong of Dana-Farber Cancer Institute, Rick Young of the Whitehead and Koch Institutes